Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Characteristics of trials included in the metanalysis ^a .

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques:

Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Comparison of balloon expandable platform vs. self-expanding platforms in high risk patients undergoing TAVR, BEV is associated with reduced risk of all-cause mortality at 30 days compared with SEV ( A ). The sub-group difference was not significant when the studies were stratified for the type of study ( B ). BEV, balloon expandable valve; SEV, self-expanding valve; TAVR, transcatheter aortic valve replacement; M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques: Comparison

Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Comparison of balloon expandable platform with old generation self-expanding platforms for to assess the role of study type (RCTs comparing BEV vs. SEV head to head with post-hoc and pre-specified analyses of RCTs) showing no between-the-group difference on the result. BEV, balloon expandable valve; SEV, self-expanding valve; TAVR, trans-catheter aortic valve replacement; M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques: Comparison

Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Comparison of balloon expandable platform vs. self-expanding platforms for cardiovascular mortality ( A ), stroke ( B ) and early safety ( C ) at 30 days in high risk patients undergoing TAVR. BEV, balloon expandable valve; SEV, self-expanding valve; TAVR, transcatheter aortic valve replacement; M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques: Comparison

Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Comparison of balloon expandable platform vs. self-expanding platforms for implantation of >1 valve per procedure ( A ), moderate to severe AR/PVL ( B ), new PPM requirement ( C ), and device success as defined by VARC ( D ) at 30 days in high risk patients undergoing TAVR. BEV, balloon expandable valve; SEV, self-expanding valve; AR, aortic regurgitation; PVL, para valvular leak; PPM, permanent pacemaker; TAVR, transcatheter aortic valve replacement; VARC, valve academic research consortium; M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques: Comparison

Journal: Frontiers in Cardiovascular Medicine

Article Title: The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis

doi: 10.3389/fcvm.2023.1130354

Figure Lengend Snippet: Comparison of balloon expandable platform vs. self-expanding platforms for life-threatening bleeding ( A ), major vascular complications ( B ), acute kidney injury ( C ), and atrial fibrillation ( D ) at 30 days in high risk patients undergoing TAVR. BEV, balloon expandable valve; SEV, self-expanding valve; TAVR, transcatheter aortic valve replacement; M-H, Mantel-Haenszel; CI, confidence interval.

Article Snippet: TAVR valve type , BEV (Sapien XT) vs. SEV (Corevalve) , BEV (Sapien 3) vs. SEV (Corevalve) , BEV (Sapien 3) vs. Acurate neo (SEV) , BEV (Sapien XT, Sapien 3) vs. SEV (Corevalve (83%), Evolut R (17%), Other non BEV was used in 5 patients) , BEV (Sapien 3) vs. SEV (Evolut R/Pro/Portico) , BEV (Sapien 3) vs. SEV (Evolut R).

Techniques: Comparison

Journal: Annals of Translational Medicine

Article Title: Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices

doi: 10.21037/atm-21-6936

Figure Lengend Snippet: Procedural characteristics, immediate results, and clinical outcomes of the study patients

Article Snippet: We implanted a 29 mm Sapien XT valve in the malpositioned CoreValve in order to eliminate the residual PVL.

Techniques:

Journal: Annals of Translational Medicine

Article Title: Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices

doi: 10.21037/atm-21-6936

Figure Lengend Snippet: Positioning the CoreValve often proved to be very difficult because of the turbulence due to the pure native aortic regurgitation. The valve may be deployed too deeply into the left ventricle and causes moderate to severe residual paravalvular leakage (PVL). In our series, all of the PVL complicating low deployments of a CoreValve prosthesis were treated by transcatheter insertion (“TAVR-in-TAVR”) of a second transcatheter heart valve. (A) In one of the patients needing CoreValve-in-CoreValve implantation, significant residual PVL was evident, owing to a lack of radial strength of the second 31 mm CoreValve to afford enough stent expansion of the first 31 mm CoreValve. The diameter of the first CoreValve frame at its waist was 24.0 mm (black double arrow), occupying the annulus in this case. Implantation of the second CoreValve increased the diameter at the waist from 24.0 to 25.6 mm (white double arrow), with significant recoil (B). In another patient with low deployment of a 31 mm CoreValve prosthesis, the diameter of the device at the aortic annulus was 27.6 mm (black double arrow) and 24.0 mm at its waist (dashed black double arrow) (C). We implanted a 29 mm Sapien XT valve in the malpositioned CoreValve in order to eliminate the residual PVL. The final diameters both at the annulus (white double arrow) and the waist (dashed white double arrow) were 29.2 mm (D).

Article Snippet: We implanted a 29 mm Sapien XT valve in the malpositioned CoreValve in order to eliminate the residual PVL.

Techniques:

Journal: Interventional Cardiology: Reviews, Research, Resources

Article Title: Transcatheter Aortic Valve Implantation for Severe Pure Aortic Regurgitation With Dedicated Devices

doi: 10.15420/icr.2021.19

Figure Lengend Snippet: Summary of Studies Available for Transcatheter Aortic Valve Implantation in Pure Aortic Regurgitation

Article Snippet: Roy et al. 2013[ ] , EGD , 14 centres worldwide , Pure AR , 43 , 75 ± 9 , 97 , 27 ± 18 , 10 ± 5 , 45 ± 13 , 59 ± 14 , 9 , CoreValve 95% Sapien XT 5% , 19% required a second valve 21% more than mild residual AR 5% major stroke 9% mortality at 30 days.

Techniques:

Journal: Current Cardiology Reviews

Article Title: Rate and Predictors of Permanent Pacemaker Implantation after 
Transcatheter Aortic Valve Implantation: Current Status

doi: 10.2174/1573403X15666181205105821

Figure Lengend Snippet: Impact of permanent pacemaker implantation after TAVI on mortality.

Article Snippet: Sapien XT CoreValve , Giustino et al . [ ] , 2016 , 947 , 17.3 , • Age • Male sex • Body mass index • Transfemoral access TAVI • CoreValve • Balloon post dilatataion • Diameter cover index > 8 units , • 1.08 per year • 1.7 • 1.08 per unit • 0.5 • 2.6 • 9.2 • 3.2 , • 1.04-1.12 • 1.1-2.7 • 1.02-1.13 • 0.3-0.9 • 1.6-4.3 • 5.5-15.5 • 1.6-6.7.

Techniques: Protein-Protein interactions, Blocking Assay

Journal: Current Cardiology Reviews

Article Title: Rate and Predictors of Permanent Pacemaker Implantation after 
Transcatheter Aortic Valve Implantation: Current Status

doi: 10.2174/1573403X15666181205105821

Figure Lengend Snippet: Predictors of permanent pacemaker implantation after TAVI.

Article Snippet: Sapien XT CoreValve , Giustino et al . [ ] , 2016 , 947 , 17.3 , • Age • Male sex • Body mass index • Transfemoral access TAVI • CoreValve • Balloon post dilatataion • Diameter cover index > 8 units , • 1.08 per year • 1.7 • 1.08 per unit • 0.5 • 2.6 • 9.2 • 3.2 , • 1.04-1.12 • 1.1-2.7 • 1.02-1.13 • 0.3-0.9 • 1.6-4.3 • 5.5-15.5 • 1.6-6.7.

Techniques: Blocking Assay

Journal: The Annals of thoracic surgery

Article Title: Stent and Leaflet Stresses in 29mm Second Generation Balloon-Expandable Transcatheter Aortic Valve

doi: 10.1016/j.athoracsur.2017.01.064

Figure Lengend Snippet: Maximum principal strain of a) 29mm and b) 26mm Sapien XT under diastolic pressure.

Article Snippet: Sapien XT Mesh Generation Fully expanded, nominal sized SapienXT (29mm) was imaged with desk-top cone-beam micro-computed tomography scanner (microCT-40; Scanco Medical AG, Baseldorf, Switzerland) in different orientations and intensities to distinguish stent and leaflet geometries.

Techniques: